Dale Ventures’ AUD$2.5 Million Investment Helps Fast-Track Rail Online

Australian railroad travel service adds North American Amtrak ticketing

Rail Online’s leadership team

Rail Online’s leadership team

SYDNEY, Aug. 27, 2022 (GLOBE NEWSWIRE) — A recent AUD$2.5 million investment from Dale Ventures has enabled Rail Online to fast-track its expansion plans. The railroad travel service now allows travelers to search, book, and ticket Amtrak journeys, with multiple currency options via a 24/7 connection to live Amtrak inventory.

In addition to the North American expansion, the investment from Dale Ventures has also helped accelerate Rail Online’s expansion plans in Australia, New Zealand, and Europe.

James Dunne, Rail Online’s CEO, says the addition of Amtrak is timely because Rail Online saw strong inquiry levels for North American rail journeys, bolstered by the pent-up demand related to the pandemic.

“By offering live booking capability,” says Dunne, “Rail Online has made it more cost-effective, efficient, and convenient for travelers to book Amtrak journeys.”

“In addition, travelers booking through Rail Online have the freedom and flexibility to self-manage all itinerary changes and refunds,” Dunne says.

Amtrak’s network connects more than 500 destinations in 46 United States and three Canadian provinces. The company’s fleet of more than 300 trains includes 20 Acela high-speed trainsets, which reach speeds of up to 240 km/h, making it the fastest passenger service in the Western Hemisphere.

Dunne says the addition of Amtrak’s North American services brings Rail Online one step closer to fulfilling its aim of being “the one-stop shop for all rail bookings for customers across the globe.”

“With this new Amtrak connection, Rail Online continues to lead the way in making rail travel easier,” says Dale W. Wood, CEO of Dale Ventures. “I congratulate James and his team for their incredible work and rapid growth.”

For bookings, visit www.rail.online.

About Dale Ventures

Dale Ventures is a personal investment holding group founded by serial investor Dale W. Wood. The company partners with management teams to provide the significant strategic and analytic resources needed to build and grow remarkable companies. Dale Ventures has adopted a consultative approach that harnesses the power of innovative teams to generate groundbreaking ideas, tactics, and strategies that drive growth and build long-term value.

For more information about Dale Wood and his projects, please visit www.Dale.com and Facebook.com/DaleVentures.

Media Contact

Dale Ventures FZE
contact.ae@dale.com
Jumeirah Lake Towers
Cluster I; Platinum Tower
12th Floor; Suite #1207
Sheikh Zayed Road
Dubai, United Arab Emirates

Related Images

Image 1: Rail Online’s leadership team

Rail Online’s leadership team (L to R): CFO Lachlan McCallum, CTO Kew Muthalif, GM Kirsty Blows, and CEO James Dunne

This content was issued through the press release distribution service at Newswire.com.

Attachment

Chicago Luxury Retailer SVRN Unveils Million Dollar Store Remodel in Tangent With Award-Winning Korean Architecture Firm WGNB

After a year of ideation and 5 months of construction, SVRN reopens, revealing an expansion totaling 4,200 square feet with unconventionally innovative architecture that transcends the traditional retail environment to deliver an immersive customer experience.

SVRN Remodel & Expansion

SVRN Remodel & Expansion

CHICAGO, Aug. 26, 2022 (GLOBE NEWSWIRE) — SVRN, Chicago multi-brand luxury retailer, announced that its West Loop storefront has now reopened with an extensive expansion and visionary remodel. Korean architecture firm WGNB, winner of Dezeen’s Emerging Interior Design Studio of the Year 2021, oversaw the redesign, paying homage to SVRN CEO David Kim’s Korean heritage and the story of perseverance that helped his family form a successful business venture. The Kim family fought through many battles to keep their business afloat, including their first store burning down and other rebuilds through the years due to looting and destruction. The remodel presents a purposeful mixture of synthetic and natural forms and materials while personifying the juxtaposition between balance and tension that has helped the Kim family business grow and evolve, eventually leading to the elevated and more conceptual SVRN. The new space elevates Chicago’s fashion retail industry, presenting the previously unseen approach of experimentalism and intersectionality. The storefront is celebrating the remodel with a grand reopening party on Sept. 1, 2022.

“By embodying the Eastern philosophy, SVRN’s lens would speak of collections that are not just the product of fashion and trends, but beyond garments,” said Jonghwan Baek, creative director of WGNB. David Kim, CEO of SVRN, agrees with Baek’s philosophy, stating, “WGNB was able to execute my family’s story of perseverance through an artistic lens, where the buildout of our store not only elevates the Chicago retail environment, but portrays a strong message.”

This announcement comes after 14 months of meticulous planning and design work, as well as a five-month closure period for SVRN. The storefront is excited to open and share this new experience with Chicago.

SVRN Remodel Details:

• WGNB’s first-ever North American project executed in tangent with HNR and Helios.

• Additional 1,200 square feet expansion.

• Materials like stainless steel and Venetian plaster are used in synchrony with naturally occurring volcanic rocks, blackened wood and linen, conveying a juxtaposition of intersectionality that is core to SVRN’s brand image.

About SVRN

SVRN is a luxury retail space in Chicago’s West Loop that carries high-end labels such as Rick Owens, Maison Margiela, Jil Sander and more. This shop is the result of 40 years of business with a story that is unlike that of any other boutique in our city. More than that, it is the result of a South Korean family immigrating to the United States with next to nothing; no resources, wealth or connections. Now seen as one of the city’s only experimental fashion storefronts, SVRN is a destination point in the United States for fashion enthusiasts both local and from abroad. With this remodel, SVRN aims to be a hub for self-expression through the intersection of fashion, art, design and culture. Feel free to access our website and Instagram. If further information is needed or you would like to attend our grand reopening event, please contact SVRN at yusra@svrn.com or +1 (630) 441-5635.

###

Related Files

WGNB_SVRN Schematic Design Submission Package_Final.pdf

BRAND DECK REDUCED SIZE 2.pdf

Related Images

Image 1: SVRN Remodel & Expansion

Photograph of the front (West) side of SVRN’s recently completed remodel and expansion. Photos courtesy of WGNB

This content was issued through the press release distribution service at Newswire.com.

Attachment

Saint Lucia Citizenship Investment Programme makes top three in the 2022 CBI Index

Castries, Aug. 26, 2022 (GLOBE NEWSWIRE) — St Lucia took third place in this year’s instalment of the CBI Index – which ranked 13 countries with operational citizenship by investment programmes.

Seen as an industry voice and reliable source for those looking to vet CBI programmes around the world, the CBI Index is published annually by the Private Wealth Management magazine, a publication of the Financial Times, and in partnership with CS Global Partners.

This year, St Lucia was ranked alongside Antigua and Barbuda, Austria, Cambodia, Dominica, Egypt, Grenada, Jordan, Malta, Montenegro, St Kitts and Nevis, Turkey, and Vanuatu.

The CBI Index ranked these jurisdictions across nine pillars including Freedom of Movement, Standard of Living, Minimum Investment Outlay, Mandatory Travel or Residence, Citizenship Timeline, Ease of Processing, Due Diligence, Family and Certainty of Product.

Having recently welcomed Mc Claude Emmanuel to the position of Chief Executive Officer of its CBI unit, St Lucia was recognised its affordable minimum investment outlay, reasonable mandatory travel or residence requirements and ease of application processing.

“This recognition means a lot to us. The CBI Index is a globally recognised report that has been assessing CBI programmes for the last six years and not only will investors gain insight into our programme but it also gives us an opportunity to improve aspects of our programme to increase our scores next year,” said notes Mc Claude Emmanuel, CEO of St Lucia’s CPI Unit.

Investors can become a citizen of St Lucia in as little as 90 days by investing only a minimum of US$100,000 through its National Economic Fund, and busy entrepreneurs are not required to stay in the country for prescribed periods of time.

There weren’t many significant changes in the minimum investment outlays since the 2021 CBI Index, this was reflected in no change in the order of the final scores.

There were also no changes from the 2021 CBI Index to scores under the Mandatory Travel or Residence Pillar – Caribbean nations continue to rank highly in this area.

The country scored 87% overall.

St Lucia scored 9 out of ten for Due Diligence, Citizenship Timeline, and Family.

A very important aspect of any CBI programme is its ability to vet applicants and ensure that only honest individuals who can account for how they make a living are accepted into the programmes.

“We are on an ongoing drive to continuously enhance the due diligence processes of our programme as we are very keen to protect its integrity and value,” noted Mc Claude Emmanuel.

With ongoing geopolitical tensions, special attention is now being given to jurisdictions that offer CBI programmes. The international community is concerned that these programmes may offer boltholes for suspect characters looking to evade the law.

International respect is vital for any CBI programme to thrive, and a layer of ongoing monitoring is becoming a key pillar of reputable CBI Units such as that of St Lucia. Caribbean nations are setting global best practices when it comes to advancements in due diligence processes.

The Citizenship Timeline Pillar looks at the average time taken for citizenship to be secured by the applicant. One of the key merits of CBI programmes is their ability to provide a rapid route to second citizenship; St Lucia was awarded top points for its short turnaround times, which takes three months for citizenship to be granted from the date the Authorised Agent is notified that the application has been accepted for processing.

The CBI Index recognises that the rise of increasingly complex family relationships is driving investors to seek programmes that allow for a more diverse range of family members to be included under a primary application.

As an additional layer of nuance to its scoring system, this year’s CBI Index also draws a distinction between family members who are allowed to apply with and obtain citizenship at the same time as the main applicant and those who can apply at a later stage and because of the main applicant has already received citizenship.

Multiple family member categories were considered, with points being awarded for adult children, parents, grandparents and even siblings. Additional merit was also given to programmes with provisions for family members of the main applicant’s spouse. Additionally, the degree of flexibility within each of these categories can differ radically from programme to programme.

St Lucia scored 8 out of 10 in the Certainty of Product pillar. This pillar encompasses a range of factors that measure a programme’s certainty across five different dimensions: longevity, popularity and renown, stability, reputation, and adaptability.

Longevity measures the age of a given programme while Popularity and renown evaluate the number of applications and naturalisations under each programme per year, as well as a programme’s eminence in the industry.

The reputation of a programme was determined by the amount of negative press or the number of scandals it has been linked to, affecting investors’ broader perceptions of the countries in which they invest. Just as important, however, is evidence that programme funds are being utilised for social good. Points were awarded for a jurisdiction’s transparent use of CBI funds, for example for the development of domestic healthcare, education, tourism and other infrastructure. One of the main ways that investors can become citizens of St Lucia is through its Economic Fund which Mc Claude Emmanuel has said will “benefit all St Lucians by investing in social interventions and assisting the country to be food secure as assistance will be given to local farmers.”

Lastly, adaptability reflects a programme’s ability to rapidly respond to, and sometimes even predict, the needs of applicants and the industry.

St Lucia continues to offer a popular programme with consistently high application volumes, stability with no caps on the number of applications or specific calls to end the programme, and adaptability both in respect of changes to keep the programme functioning during Covid-19 and its swift response to the Russian invasion.

St Lucia, along with Antigua and Barbuda, Dominica, Grenada and St Kitts and Nevis scored seven out of 10 in the Freedom of Movement pillar. St Lucia has access to 15 of the 20 key business hubs assessed in the 2022 CBI Index.

Lastly, St Lucia scored six out of 10 for its decent freedom, GDP growth and GNI scores.

Download the full CBI Index here, to get further insights into the CBI industry and a full evaluation of the CBI programmes of the 12 other jurisdictions in the rankings.

PR St lucia
Saint Lucia
+1 758 458 6050
mildred.thabane@csglobalpartners.com

Thailand reports sixth confirmed monkeypox case

A Thai woman, returning from Qatar, has become the sixth confirmed monkeypox case in Thailand, according to Dr. Opart Karnkawinpong, director-general of the Disease Control Department.

He said yesterday (Friday) that the 21-year-old native of the north-eastern province of Maha Sarakham worked at a traditional Thai massage parlour in Qatar. She developed blisters on her genitals on August 10th and flew back to Thailand on August 21st. She then immediately returned to her hometown and went to see a doctor at the district hospital the following day.

The doctor thought she might be infected with monkeypox and took specimens, which were sent to the Medical Sciences Department in Bangkok for analysis, which subsequently confirmed the monkeypox infection.

Dr. Opart said that 28 people were found to have been in contact with the infected woman, but only four of them were classified as being at high risk. All 28 have, however, been advised to monitor their condition.

The five previous confirmed monkeypox cases include a Nigerian man in Phuket who left Thailand and was treated in Cambodia, a 47-year-old Thai man in Bangkok who had history of having sex with men, a German tourist in Phuket, a Thai woman in Bangkok and a Thai woman who returned from Dubai.

Source: Thai Public Broadcasting Service

Thailand’s Unemployment Rate Fell In Q2

BANGKOK, Thailand’s unemployment rate dropped to 1.37 percent in the second quarter of 2022, from 1.53 percent in the previous quarter, official data showed yesterday.

The rate was the lowest since the COVID-19 pandemic started, fuelled by the continuing economic recovery, the Office of the National Economic and Social Development Council, said, yesterday.

The number of people in the labour force amounted to 39 million, in the second quarter of 2022, representing a 3.1 percent year-on-year increase, mainly due to a growth in non-agricultural employment, such as, in retail and transportation, according to the report.

The working hours have also increased steadily, approaching the pre-pandemic level, the report said.

However, the agency noted that, employment in both the construction industry and hotel/restaurant industry has decreased, due to economic uncertainties and slow recovery of the tourism industry.

The report also indicated a labour shortage in the near future, as the country’s economy is improving.

Source: Nam News Network

The rise to power of ‘big brother’ Prawit Wongsuwan, new caretaker PM

Deputy Prime Minister Gen Prawit Wongsuwan is generally considered a weak link in Prayut Chan-o-cha’s administration, tainted by the scandal over a multimillion-baht wristwatch collection, despite his repeated denials of corruption. But in a twist of fate, he finally finds himself in the top post of prime minister, thanks to a legal dispute over the tenure of his junior Army classmate.

The Constitutional Court on Wednesday voted 5:4 to suspend PM Prayut from duty after it decided to accept a petition filed by the opposition asking for a ruling on his eight-year term as prime minister. Prayut will be suspended as PM until the ruling is delivered, though he can continue to serve as defense minister in the Cabinet.

Prawit, who is leader of the ruling Palang Pracharath Party, tops the hierarchy of the six deputy prime ministers, so he automatically became caretaker prime minister following Prayut’s suspension. Prawit will remain as caretaker PM until the Constitutional Court issues its ruling on Prayut’s tenure.

The caretaker PM has full authority to reshuffle the Cabinet or dissolve the House of Representatives, according to Deputy Prime Minister Wissanu Krea-ngam, the government’s legal expert.

Big brother of ‘3Ps’

Prawit, now 77, is known as the “big brother” of the Burapha Payak (“Tigers of the East”) military clique of officers, who typically start their careers in the 21st Infantry Regiment based in Prachinburi. This group includes former Commander-in-Chief Anupong Paochinda and his successor Prayut. The trio of generals is dubbed the “3Ps” – Prayut, Prawit and “Pock” (Anupong).

While Prayut led the coup that toppled the Yingluck government in 2014, Prawit is widely credited with helping the military prolong its power after the 2019 general election.

In June 2020, as chief party strategist, Prawit was elected as Palang Pracharath’s new leader. He won the top seat uncontested, announcing he would accept the post to end internal disputes as it would allow him to handle party infighting. “They [the factions] must be reconciled,” he said.

His rise to party chief was expected to quell an ongoing power struggle within Palang Pracharath, which has many factions.

Armed with strong political connections and eight years’ experience in politics, Prawit is well versed in dealing – and bargaining – with party members. Colleagues describe him as a man of charisma and influence with the ability to make party politicians toe the line.

Some analysts describe him as the country’s most influential retired general. With his strong military connections and influence, Prawit as new party leader was expected to help the Palang Pracharath-led government and PM Prayut cement their power for the long term.

‘Secret deal’ with Thaksin?

Prawit has strong connections with business tycoons and politicians across the spectrum, including coalition partners like Bhumjaithai and the Democrats and even the main opposition Pheu Thai Party.

Recent reports speculated that Prawit and fugitive PM Thaksin Shinawatra had made a “secret deal” for Palang Pracharath to join hands with Thaksin’s proxy Pheu Thai to form the next government after the coming election.

The deal reportedly spurred the government’s U-turn over the party-list MPs calculation, switching from dividing the votes by 500 (the total number of MP seats) to 100. The 100 method would increase the chance of large parties, especially Pheu Thai, gaining an absolute majority in the House.

Souring of ties with Prayut

As Prayut’s popularity started to decline last year, an attempt was made to unseat the premier led by then Palang Pracharath secretary-general Thamanat Prompow. It was rumored that Thamanat, who is close to Prawit, collaborated with the 10 single-MP micro-parties to vote against Prayut in last September’s censure debate.

But the failure of the plot led to Thamanat being ousted both as deputy agriculture minister and party secretary-general. He finally found a new home in the Thai Economic Party.

Since then, Prawit and Prayut have reportedly been at odds. Once closely united, the three brothers-in-arms have seen ties sour recently, particularly between Prawit and Prayut. The trio’s “little brother”, Prayut, appears to have lost support from his big brother, analysts say.

According to reports, some ruling party MPs have even tried to replace Prayut with Prawit as PM or wanted the latter to take over as interior minister from Anupong.

Confirmed bachelor at 77

Born on August 11, 1945, in Bangkok, Prawit has remained single despite rumors of amorous relationships in recent years.

“I am single, and I can be in a relationship with anyone. It’s my business when I get married or if I am seeing someone,” he told the press in 2016 following a surge of media speculation.

Prawit graduated from the Armed Forces Academies Preparatory School in 1965 and entered Chulachomklao Royal Military Academy. After graduating in 1969, he became an officer in the 21st Infantry Regiment (Queen’s Guard) of the Second Infantry Division.

It was during those early days in the military that Prawit met his brothers-in-arms Prayut and Anupong – who now serves as interior minister. Part of the famous Burapha Payak military clique, all three went on to head the Royal Thai Army as commander-in-chief.

Prawit was appointed Army chief in October 2004 under Thaksin Shinawatra’s government, serving until his retirement in September the following year. After the 2006 military coup which overthrew Thaksin, Prawit was appointed to the National Legislative Assembly.

He served as defense minister in the Democrat-led government of Abhisit Vejjajiva from December 2008 until August 2011. Prawit became a key figure in the emergency center set up to deal with the 2010 anti-government protests, which ended in a deadly crackdown by troops that left nearly 100 dead.

After the May 2014 coup led by then Army chief Prayut, Prawit was appointed deputy chairman of the junta’s National Council for Peace and Order (NCPO), as well as deputy prime minister and defense minister in Prayut’s post-coup Cabinet – and later chairman of the committee tasked with selecting members of the current Senate.

Luxury watch controversy

Prawit has been hounded by scandal ever since he was spotted wearing ultra-luxury wristwatches on several occasions, prompting accusations of “unusual wealth”. None of the watches – 25 in total – were listed on his mandatory asset declarations filed with the National Anti-corruption Commission (NACC) when he took office following the 2014 coup.

His 25 undeclared watches were worth almost 40 million baht in total, with prices ranging from about 413,000 baht for a Rolex to 3.6 million baht for a Patek Philippe.

Prawit claimed the timepieces were loaned to him by a billionaire close friend and had been returned to the owner’s family after his death. Following a two-year investigation that included an interrogation of the deceased billionaire’s two daughters, the NACC ruled Prawit innocent of wrongdoing for failing to declare the borrowed watches.

The agency said that the loaned watches should not be considered Prawit’s debts or assets as they did not belong to him.

Source: Thai Public Broadcasting Service

THG Chairman banned from holding an executive post for 42 months

Thailand’s Securities and Exchange Commission (SEC) has agreed to bar Thonburi Healthcare Group (THG) Chairman and CEO Dr. Boon Vanasin from holding any executive post in the company for 42 months and has fined him 2.3 million baht for alleged share price manipulation.

The SEC said that the 42-month ban will take effect only when Dr. Boon agrees to accept the financial sanction. If not, the SEC will take legal action against him in Civil Court.

Dr. Boon was faulted by the SEC for violating Section 240 of the Securities and Exchange Act B.E. 2535 (1992) by disseminating information to the media in July last year, claiming that THG was in the process of signing a deal to procure Pfizer mRNA vaccine, with the first lot of five million doses expected in Thailand in August of that year.

Such a report could cause misunderstanding concerning the performance of the company which, in turn, could affect the company’s share price, according to the SEC.

Dr. Boon had claimed that THG was in the process of closing the deal with a government agency, which he declined to name. The claim was, however, subsequently refuted by both Pfizer-BioNTech and the Government Pharmaceutical Organisation (GPO).

He then told Thai online media “Kom Chad Luek” that the deal was with the Defence Ministry, but this was also denied by the ministry’s spokesman.

In July last year the SEC received a complaint, claiming that Dr. Boon’s statement to the media about the vaccine deal might constitute share price manipulation.

A THG official sent an urgent letter to the Stock Exchange of Thailand, denying that Dr. Boon had ever told Thai media about the vaccine deal with the Defence Ministry, but claimed that it was trying to procure mRNA and other vaccines “for Thai people”.

On August 4th last year, Dr. Boon announced he had given up all efforts to procure mRNA vaccines because it was too difficult.

At the time, several private hospitals had tried to procure mRNA vaccines via state agencies, to meet demand from people who could afford and wanted to pay for the vaccines, because they did not trust the effectiveness of the Chinese-made Sinovac vaccine, which was being provided free of charge.

Only the Chulabhorn Royal Academy, GPO, the Disease Control Department, the National Vaccine Institute and the Thai Red Cross Society were then authorised to procure vaccines directly from the manufacturers.

Dr. Boon and his wife, Charuvan, are major shareholders in THG. THG’s share price soared 13.45% to 31.50 baht on July 15th last year, after he told the media about the vaccine deal. The share price fell back to 28.25 baht on August 6th following news of the collapse of the deal.

Source: Thai Public Broadcasting Service

Kanine Group Launches Dog Apparel, Accessories and Home Products With Boss Dog Accessories, Warner Brothers’ DC League of Super-Pets and Kanine Brands

Kanine Brand

Kanine Brand

DUBLIN, Aug. 26, 2022 (GLOBE NEWSWIRE) — Kanine Pets World Limited, a subsidiary of Kanine Group, launches today (International Dog Day) on www.kanine.com products for dogs, which will include apparel (hoodies, padded jackets, bomber jackets, sweaters, polo shirts etc), accessories (collars, leashes and harnesses, bags), home products (beds, bowls, mats, travel bags etc) and toys for the brands BOSS Dog Accessories, DC League of Super-Pets and its own brand Kanine with many more international brands to follow.

“We’re so excited to launch kanine.com and to redefine the ecosphere of premium pet products for pawrents and their furbies. Kanine’s journey to bring something to everyone starts today with premium fashion such as BOSS Dog Accessories, superhero power such as DC League of Super-Pets and our own collection of Kanine products. This is only the beginning and we have a very strong pipeline of new and exciting brands and products to come. We’re very much looking forward to expanding the Kanine ecosphere,” says Samuel Wong, CEO and CFO, Kanine Group.

“It’s so amazing to launch Kanine.com, which will be the go-to place for dogs’ premium fashion and lifestyle products. I’ve worked with many of our partners on their adult and kids lines before and it’s amazing to now be able to add pets to the family! Our own Kanine brand is the quintessential ‘mini me’ brand for dogs so you can dress your pups in the same fashion colours and styles you wear yourself,” stated Sean Coxall, CMO, Kanine Group.

BOSS Dog Accessories launches with its first Fall Winter 2022 collection with a premium collection of fashionable dog apparel that ties with the BOSS adult wear designs and colours. The products are available worldwide in the online stores hugoboss.com and kanine.com, as well as in selected BOSS Stores, department stores and pet stores.

The “DC League of Super-Pets” range launches with Warner Bros. Pictures releasing the film in theaters only. The products are available in the greater Asia region on kanine.com, as well as in selected department stores and pet stores.

The Kanine range is a collection of fashionable dog apparel and accessories that have a preppy feel based on primary colours that match consumers’ lifestyle, enabling their dogs to have the same ‘mini me’ look as them. The collection of accessories such as collars, harnesses, and leads cater to small to large dogs with a versatile yet stylish look.

About Kanine Group:

Kanine Group designs, sources, and globally distributes pet apparel and accessories under various owned and licensed brands, including its namesake Kanine brand, and operates www.kanine.com, an exclusive platform for premium and exciting products, including apparel, accessories and home products for pets. Follow Kanine on FacebookInstagramTwitter and LinkedIn.

If you have any questions, please contact:

Sean Coxall

Chief Marketing Officer

E-mail: sean@kanine.com

WEBSITE : https://www.kanine.com

LINKEDIN: KANINE-INT

INSTAGRAM: BRAND_KANINE

FACEBOOK: BRANDKANINE

TWITTER: BRAND_KANINE

Related Files

Kanine Launch announcement Aug 26 copy.pdf

Related Images

Image 1: Kanine Brand

Kanine Brand Sweater

This content was issued through the press release distribution service at Newswire.com.

Attachment

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

August 26, 2022

Philips AI-powered interventional and diagnostic smart systems and at-home solutions connect care across the cardiology care pathway to enhance diagnostic confidence, drive greater efficiency, and improve patient outcomes

Amsterdam, the Netherlands and Barcelona, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest integrated cardiology solutions at the European Society of Cardiology (ESC) Congress (August 26-29, Barcelona, Spain). The company’s newest innovations in cardiology help provide enhanced clinical insights, strengthen clinical confidence, drive efficiency in critical care and improve cardiac care experiences from diagnosis and treatment to home care.

The demands on cardiology departments have never been higher, driving clinicians to balance the delivery of high-quality care for a growing volume of complex patients with pressures to improve departmental efficiency. The Future Health Index 2022 global report commissioned by Philips shows cardiology leaders not only see technology infrastructure improvements as key to managing and monitoring patients over extended periods of time in out-of-hospital settings, but also key to better diagnosing and treating the rising demand of new patients.

“As health systems navigate increased demand for cardiology services and complexity of patients, they face an ongoing challenge to provide quality patient care while adjusting to an increased focus on outcomes, efficiency, and costs,” said Dr. Alexandra Goncalves, Chief Medical Officer, Precision Diagnosis at Philips. “With our innovation in cardiology, Philips is uniquely positioned to deliver definitive diagnostics and enable personalized patient management to help improve cardiac care with greater efficiency, enhanced clinical insights and better experiences for patients and staff.”

Powerful ecosystem for cardiovascular care
Philips software-defined systems deliver data-driven insights, supported by AI, to provide the right care at the right time to help better manage even the most complex cardiology cases. Smart integrated end-to-end technology streamlines communication between devices and systems to help identify and address clinical as well as operational improvements, strengthen clinical confidence, build workflow efficiency, optimize resources and help lower the cost of care. Visitors to the Philips booth at ESC will see how the company is transforming cardiac care delivery into a connected future by integrating imaging, devices, software, informatics and services including:

  • Precision diagnosis for cardiology – Clinically smart diagnostic solutions, streamlined workflows and actionable insights for data-driven cardiac care identify clear pathways for the most complex patient journeys. Advanced visualization solutions include Philips vendor-neutral, multi-modality image and information management workspace  – IntelliSpace Cardiovascular – and its new echocardiography viewing, analysis and reporting workspace (Ultrasound Workspace), a scalable solution making its debut in the European market at ESC, that when combined with Philips Ultrasound System (EPIQ CVx), leverages AI across a wide range of applications to provide advanced quantification and standardization with consistent on and off-cart applications. Together, these echocardiology workflow solutions help improve diagnostic confidence, enhance outcomes and operational effectiveness. Philips has also expanded access to hemodynamics at point of care for real-time blood flow assessment on its Lumify Handheld Ultrasound. In addition, Philips will spotlight its award-winning Spectral CT 7500 for exceptional cardiac imaging for a full cardiac assessment to help improve cardiac treatment pathways, and its cardiac MR portfolio of solutions including the helium-free MR 5300, Smart Workflow and AI-powered SmartSpeed, also debuting in Europe at ESC.
  • Minimally-invasive treatment – Philips solutions for image-guided minimally invasive therapy help physicians to decide, guide, treat and confirm the right care for every cardiac patient in real time. Built on Philips Image-Guided Therapy System – Azurion – the company’s next generation image-guided therapy platform, these solutions uniquely integrate best in class imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. At ESC, Philips will demonstrate how its innovative EchoNavigator software enables users of its EPIQ CVxi interventional cardiology ultrasound system to automatically fuse real-time 3D TEE (transesophageal echocardiography) with cardiac fluoroscopy X-ray imaging to monitor and assist catheter-based cardiac operations. Also featured is Coronary Suite, a fully integrated system for confident decision-making to help improve cardiac cath lab performance during percutaneous coronary intervention (PCI) procedures, and hemodynamic workflow for continuous monitoring, seamless data flow and continuity for cath lab patients.
  • Ambulatory monitoring & diagnostics – Philips’ portfolio of remote cardiac care solutions includes near real-time patient monitoring, telehealth, emergency and therapeutic care, and cardiac ambulatory diagnostics and monitoring solutions to provide confident care across post-acute settings for chronic disease and readmission management. Solutions, which help to enable smooth transitions from the hospital to the home, include the Philips Extended Holter – ePatch for up to 14 days of continuous, high-quality ECG recording for reliable diagnosis [1], with robust data analysis provided by cloud-based, AI-enabled Philips Cardiologs software. A recent Cardiologs study demonstrated how AI may soon predict occurrence of atrial fibrillation. Also featured at ESC is Philips Questionnaire Manager, a cloud-based SaaS solution to better manage patient reported outcomes, and Philips Care Engagement Manager, helping empower clinicians to provide the right care at the right time, in the right place, while also engaging cardiac patients to take a more active role in their at-home recovery.

Philips’ hosted cardiac ultrasound symposium session at ESC 2022
As cardiology leaders look ahead to what’s next in diagnosing and treating heart failure, Philips will host a Cardiac Ultrasound Satellite Symposium session at ESC – Echo in heart failure, what can we do better now?  – Friday, August 26 at 3:30pm CET, and streamed live for those who are not attending ESC in person. The session will feature international thought leaders across the Netherlands, Italy and Spain who will share their insights on horizons in structural heart disease, the reality of using 3D for routine heart failure patients, and clinical experience with the fusion revolution. Visit Philips at ESC for more information.

Visit Philips Cardiology to learn how the company’s integrated systems, devices, informatics, software and services help deliver quick, confident diagnosis and effective treatment to improve outcomes for cardiovascular disease patients. Join Philips at ESC (Hall 3, Booth #K155) to hear how its data-driven, AI-powered smart systems and solutions help strengthen clinical confidence, streamline cardiac imaging workflows and improve the cardiac care experience for patients and staff.

[1] Patient will need to replace patch on day 5 of wear, or sooner as required.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978 221 8919
E-mail: Kathy.OReilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

— the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA

SHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the “FDA”) concerning the approval of the investigational new drug (“IND”) application for XPO1 inhibitor WJ01024 tablets (product code: “JS110”) by the FDA. So far, 6 innovative drugs in Junshi Biosciences’ pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.

About JS110
JS110 is a small molecule inhibitor of the nuclear export protein XPO1, which is clinically intended for the treatment of patients with advanced tumors. According to the results of pre-clinical studies, JS110 specifically blocks the function of XPO1, inhibits the nuclear export of various tumor suppressor proteins including p53, and strengthens the functions of tumor suppressor proteins. In vitro, JS110 inhibits the growth and induces death of various tumor cells; in animal tumor models, JS110 monotherapy and combination therapy can both inhibit the growth of various blood and solid tumors. Due to its unique mechanism of action, the development of JS110 may potentially bring new treatment options to patients with advanced tumors.

In April 2021, the IND application for JS110 was approved by the National Medical Products Administration. At present, the Phase I clinical trial of JS110 is in progress in the People’s Republic of China (NCT04991129).

Junshi Biosciences currently owns the world-wide exclusive production rights, licensed production rights and sales rights for JS110.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir/ritonavir (“PAXLOVID”) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800